复发缓解型多发性硬化症患者临床疾病发作时无血浆蛋白质组学特征与11年临床、认知和MRI结果相关。
No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients.
作者信息
Bridel Claire, Eijlers Anand J C, van Wieringen Wessel N, Koel-Simmelink Marleen, Leurs Cyra E, Schoonheim Menno M, Killestein Joep, Teunissen Charlotte E
机构信息
Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands.
Department of Anatomy and Neurosciences, MS Center Amsterdam, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands.
出版信息
Front Mol Neurosci. 2018 Oct 31;11:371. doi: 10.3389/fnmol.2018.00371. eCollection 2018.
The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.
复发缓解型多发性硬化症（RRMS）的临床病程高度异质性，且缺乏诊断时的预后生物标志物。我们研究了RRMS患者诊断时血浆蛋白质组的预测价值。使用基于新型适体的蛋白质组学平台对血浆蛋白质组进行检测，该平台可测量一组预先定义的1310种蛋白质的水平。在67例临床和放射学特征明确的RRMS患者中，我们发现诊断时的血浆蛋白质组与11年后的临床、认知或MRI结果之间无关联。脑脊液蛋白质组学研究可能更适合于识别早期RRMS中的预后生物标志物。
Zotero 插件